Acromegaly Clinical Trials

206 clinical trials for Acromegaly across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly — RECRUITING
• A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs — RECRUITING · PHASE3
• Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA — RECRUITING
• Study of MAR002 in Healthy Men — RECRUITING · PHASE1
• Effects of Pasireotide Lar Therapy on Bone Metabolism — RECRUITING
• Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study — RECRUITING
• The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly — RECRUITING
• Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. — RECRUITING
• The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research — RECRUITING
• Developing a Simple Recognition System of Acromegaly — RECRUITING
• EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY — COMPLETED · PHASE3
• Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert); Prospective, open-label study to evaluate the efficacy of the combined treatment of somatostatin analogue octreotide (Sandostatin) or dopamine agonist cabergoline (Dostinex) in patients with acromegaly on stable therapy of pegvisomant (Somavert). — COMPLETED · PHASE4
• Study of efficacy and safety of pasireotide LAR in patients with inadequately controlled acromegaly. — COMPLETED · PHASE3
• the effect of the addition of pegvisomant on quality of life and glucose sensitivity in acromegaly patients — ACTIVE_NOT_RECRUITING · PHASE3
• An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist in acromegalic patients not adequately controlled by conventional regimen — COMPLETED · PHASE3
• Acromegalia — COMPLETED · PHASE2
• "High-dose lanreotide in patients with acromegaly" — COMPLETED · PHASE3
• Use of somatostatin analogue therapy as primary medical treatment of acromegaly — COMPLETED · PHASE2
• ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly — TERMINATED · PHASE2
• A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) — TERMINATED · PHASE2
• A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs. — TERMINATED · PHASE3
• Korean Regulatory Post Marketing Surveillance for Somavert — COMPLETED
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly — TERMINATED · PHASE3
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) — TERMINATED · PHASE3
• A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) — NOT_YET_RECRUITING · PHASE1
• Direct Versus Video Laryngoscopy in Patients With Acromegaly — NOT_YET_RECRUITING
• An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE) — OTHER · PHASE2
• A Study to Evaluate MAR002 for Acromegaly — NOT_YET_RECRUITING · PHASE2
• ACRODAT Prospective Evaluation Study — COMPLETED
• A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands — OTHER · PHASE3
• A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly (PATHFNDR-2) — OTHER · PHASE3
• Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly — COMPLETED
• A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly — OTHER · PHASE2
• A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly — COMPLETED · PHASE3
• Reproducibility and Utility of OGTT in Acromegaly — COMPLETED · NA
• A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) — TERMINATED · PHASE1
• Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active Acromegaly — COMPLETED · NA
• A Prospective Study of Outcome After Therapy for Acromegaly — COMPLETED
• Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteers — OTHER
• A Phase 1 Study of TE-8214 Solution in Healthy Volunteers — COMPLETED · PHASE1
• Treatment Patterns and Treatment Outcomes for Acromegaly — COMPLETED
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) — COMPLETED · PHASE2
• An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) — COMPLETED · PHASE2
• Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs — WITHDRAWN
• A Phase 3, open-label, single-arm, multi-center trial to assess the long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly — OTHER · PHASE3
• Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China — COMPLETED
• PegvisOMant and the Immune SystEm (PROMISE) — COMPLETED
• A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly — COMPLETED
• A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly — COMPLETED · PHASE2
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies — COMPLETED · PHASE4

Refine this search